Investors & Media
4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy. The 4DMT platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Learn more about our pipeline HERE.
Latest Corporate Presentation
May 10, 2022 at 11:40 AM EDT
February 16, 2022 at 5:00 PM EST